Royal Bank of Canada continued to hold its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 56,173 shares of the biopharmaceutical company’s stock at the end of the second quarter. Royal Bank of Canada owned about 0.31% of Xenon Pharmaceuticals worth $177,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. KCG Holdings Inc. purchased a new position in Xenon Pharmaceuticals during the 1st quarter worth $122,000. K2 Principal Fund L.P. boosted its holdings in Xenon Pharmaceuticals by 40.6% during the 2nd quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock worth $518,000 after acquiring an additional 47,535 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Xenon Pharmaceuticals by 90.1% during the 1st quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock worth $868,000 after acquiring an additional 102,890 shares during the last quarter. 55.47% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have issued reports on XENE. Jefferies Group LLC set a $5.00 price objective on shares of Xenon Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 4th. Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, October 5th.

In other news, Director Mohammad Azab acquired 15,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were purchased at an average cost of $2.22 per share, with a total value of $33,300.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 9.40% of the stock is owned by insiders.

Xenon Pharmaceuticals Inc. (XENE) opened at $2.30 on Friday. Xenon Pharmaceuticals Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $9.95.

COPYRIGHT VIOLATION WARNING: “Royal Bank of Canada Has $177,000 Holdings in Xenon Pharmaceuticals Inc. (XENE)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Stock Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.